While these two genes tend to be expressed only in the thalamus in the clinical stage, KRAS and CLTC downregulation was consistently significant in the clinical stage of disease in both CNS areas, and both genes have been previously reported to be downregulated in AD [79, 80]. The gene discussed is CLTC; the disease is Alzheimer disease.